HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism.

AbstractBACKGROUND:
The development of effective drug delivery systems capable of transporting small interfering RNA (siRNA) has been elusive. We have previously reported that colorectal cancer tumor xenograft growth was arrested following treatment with liposomal preparation of siDCAMKL-1. In this report, we have utilized Nanoparticle (NP) technology to deliver DCAMKL-1 specific siRNA to knockdown potential key cancer regulators. In this study, mRNA/miRNA were analyzed using real-time RT-PCR and protein by western blot/immunohistochemistry. siDCAMKL-1 was encapsulated in Poly(lactide-co-glycolide)-based NPs (NP-siDCAMKL-1); Tumor xenografts were generated in nude mice, treated with NP-siDCAMKL-1 and DAPT (γ-secretase inhibitor) alone and in combination. To measure let-7a and miR-144 expression in vitro, HCT116 cells were transfected with plasmids encoding the firefly luciferase gene with let-7a and miR-144 miRNA binding sites in the 3'UTR.
RESULTS:
Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulation of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms, respectively. A corresponding reduction in let-7a and miR-144 specific luciferase activity was observed in vitro. Moreover, an upregulation of EMT inhibitor miR-200a and downregulation of the EMT-associated transcription factors ZEB1, ZEB2, Snail and Slug were observed in vivo. Lastly, DAPT-mediated inhibition of Notch-1 resulted in HCT116 tumor growth arrest and down regulation of Notch-1 via a miR-144 dependent mechanism.
CONCLUSIONS:
These findings demonstrate that nanoparticle-based delivery of siRNAs directed at critical targets such as DCAMKL-1 may provide a novel approach to treat cancer through the regulation of endogenous miRNAs.
AuthorsSripathi M Sureban, Randal May, Fadee G Mondalek, Dongfeng Qu, Sivapriya Ponnurangam, Panayotis Pantazis, Shrikant Anant, Rama P Ramanujam, Courtney W Houchen
JournalJournal of nanobiotechnology (J Nanobiotechnology) Vol. 9 Pg. 40 (Sep 19 2011) ISSN: 1477-3155 [Electronic] England
PMID21929751 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Dipeptides
  • Intracellular Signaling Peptides and Proteins
  • MAS1 protein, human
  • MIRN144 microRNA, human
  • MIRN200 microRNA, human
  • MYC protein, human
  • MicroRNAs
  • N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
  • NOTCH1 protein, human
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-myc
  • Receptor, Notch1
  • Transcription Factors
  • mirnlet7 microRNA, human
  • DCLK1 protein, human
  • Doublecortin-Like Kinases
  • Protein Serine-Threonine Kinases
Topics
  • Animals
  • Carcinoma (drug therapy)
  • Colorectal Neoplasms (drug therapy)
  • Dipeptides (pharmacology)
  • Doublecortin-Like Kinases
  • Down-Regulation
  • Gene Expression Regulation, Neoplastic (drug effects)
  • HCT116 Cells
  • Humans
  • Intracellular Signaling Peptides and Proteins (pharmacology)
  • Mice
  • Mice, Nude
  • MicroRNAs (metabolism)
  • Nanoparticles (administration & dosage)
  • Protein Serine-Threonine Kinases (pharmacology)
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins c-myc (metabolism)
  • Receptor, Notch1 (metabolism)
  • Transcription Factors (metabolism)
  • Up-Regulation
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: